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teal Disease: Late Outcomes Are Equivalent
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Vikram Paruchuri, Viendra I. Patel, Kenneth Rosenfield, Richard P. Cam-
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Introduction and objectives: Several trials have reported early supe-
riority of stenting over balloon angioplasty (POBA), yet long-term data are
sparse. The goal of this study was to contrast long-term clinical outcomes
and costs of these two treatment options.
Methods: Consecutive patients undergoing POBA or stenting of the
native femoral/popliteal arteries from January 2002 to May 2009 were
included. Patients were divided into two groups, PTA alone or stenting.
Study end points included actuarial 5-year primary patency (using strict
criteria of any hemodynamic change regardless of symptoms or reinterven-
tion), 5-year limb salvage, 5-year survival, and hospital cost.
Results: During this period, 815 primary procedures were performed,
511 POBA and 304 stenting. The mean follow-up duration was 33 months
(range, 0-98 months). Similar demographics were observed between two
groups. Treatment indications and TASC status are reported in the Table.
There was no difference in overall 5-year primary patency (POBA, 28% 
4%; stenting, 24%  6%; P  .31), nor was there a difference in 5-year limb
salvage in critical limb ischemia (CLI) patients (POBA, 80% 4%; stenting,
75%  10%; P  .18). There was no difference in 5-year survival in
claudicants (POBA, 71%  6%; stenting, 76%  6%; P  .65) or CLI
(POBA, 29%  5%; stenting, 36%  10%; P  .4). Procedural cost of
stenting was 60% more than POBA (P  .001) regardless of treatment
indications. When used for claudication, stenting added an additional 40%
(P  .001) to the hospital cost compared with POBA.
Conclusions: Long-term outcomes between POBA and stenting were
equivalent when stratified by indications. Stenting added significantly to
overall costs. These data support a posture of selective stenting in the
treatment of superficial femoral/popliteal lesions.
Table. Treatment indications and TASC status
Variable POBA Stents P
No. (%) No. (%)
Patients, total 511 304
Indications
Claudication 303 (59) 221 (73) .02
CLI 210 (41) 86 (28) .02
TASC
TASC A 149 (29) 59 (19) .05
TASC B 318 (62) 168 (55) 0.3Table. Continued.
Variable POBA Stents P
No. (%) No. (%)
TASC D 19 (4) 29 (10) .02
Mean  SD Mean  SD
5-year outcomes
Overall primary patency 28%  4% 24%  6% .31
CLI limb salvage 80%  4% 75%  10% .185
Claudication survival 71%  6% 76%  6% .65
CLI survival 29%  5% 36%  10% .405
Endovascular Management As First Therapy for Chronic Total Occlu-
sion (CTO) of the Lower Extremity Arteries: 2-Year Results
Katherine Gallagher, Ashley Graham, Sikandar Z. Khan, Muhammad A.
Khan, Harry Bush, James F. McKinseyNew York Presbyterian Hospital,
New York, NY
Introduction and objectives: The management of chronically oc-
cluded lower extremity (LE) arteries is one of the more challenging issues for
endovascular therapy. Not only is the procedure more complicated, the
long-term patency has been a concern. We reviewed our prospectively
maintained database to evaluate the long-term effectiveness of the endovas-
cular treatment of chronic total occlusions (CTOs).
Methods: We reviewed our prospectively maintained LE database
between March 2004 and April 2010. All CTO lesions were evaluated.
Treatments included angioplasty (PTA), atherectomy (Ath), or PTA with
stent (PTAS). A dedicated research team independently evaluated the
preprocedure, intraprocedure, and postoperative angiographic and nonin-
vasive duplex imaging, as well as clinical follow-up data. Primary (PP),
primary assisted (PAP), secondary (SP) patency, and limb salvage (LS) were
calculated.
Results:A total of 2800 lesions were treated in 1233 patients, with 688
CTOs identified. Lesions were divided by location SFA (n 193), popliteal
(n  67), tibial (n  217), and multilevel (n  211). PP, SP, and LS at 2
years were 40.1  6.7, 74.9  6.1, and 81.1  7.3 for SFA lesions treated
with PTAS and 44.0  7.0, 79.9  5.3, and 90.5  6.7 for Ath,
respectively. Tibial vessel PP, SP, and LS were 51.1  6.2, 56.2  6.2, and
66.8  7.1 for PTA and 50.2  5.6, 66.5  5.1, and 76.5  5.9 for Ath
(Tables I, II and III)
Conclusions: The endovascular management of CTOs has excellent
2-year results for SP and good PP and PAP. PTA alone in the SFA has
relatively poor long-term results and should be discouraged. Although
reintervention maybe required, endovascular therapy should be consideredTASC C 33 (6) 52 (17) .002 the primary therapy for CTOs and surgical bypass reserved for failed endo-
vascular therapy.
Table I. Patency of SFA CTO
Patency variable No. 6 mo 12 mo 18 mo 24 mo
Primary patency
PTA  stent 97 83.0  4.2 51.2  6.3 42.8  6.5 40.1  6.7
PTA 21 64.6  10.8 53.9  11.4 42.4  11.5 30.3  11.0
Ath 75 77.7  5.1 56.2  6.5 49.5  6.8 44.0  7.0
P (PTAS vs PTA) .044 .675 .621 .402
P (PTAS vs Ath) .483 .952 .964 .972
P (PTA vs Ath) .137 .509 .413 .270
Primmary assisted patency
PTA  stent 97 86.7  3.8 69.3  5.8 64.3  6.4 61.1  6.8
PTA 21 64.6  10.8 53.9  11.4 47.9  11.6 35.9  11.4
Ath 75 82.1  4.7 67.6  6.1 63.1  6.4 55.2  7.1
P (PTAS vs PTA) .012 .076 .076 .032
P (PTAS vs Ath) .538 .643 .640 .515
P (PTA vs Ath) .045 .118 .115 .077
Secondary patency
PTA  stent 97 91.7  3.0 93.1  4.6 78.0  5.5 74.9  6.1
PTA 21 69.7  10.4 64.3  10.9 57.9  11.5 45.0  12.0
Ath 75 84.6  4.5 84.6  4.5 79.9  5.3 79.9  5.3
P (PTAS vs PTA) .004 .027 .030 .010
P (PTAS vs Ath) .578 .948 .975 .814
P (PTA vs Ath) .020 .021 .026 .004
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Popliteal No. 6 mo 12 mo 18 mo 24 mo
Primary patency
PTA 32 85.9  6.6 58.4  10.3 52.6  10.8 52.6  10.8
Atherectomy 35 67.8  8.5 64.0  8.8 56.0  9.4 51.3  9.7
P .122 .944 .867 .736
Primary assisted patency
PTA 32 89.5  6.6 70.6  9.6 64.8  10.4 64.8  10.4
Atherectomy 35 80.4  7.3 72.7  8.4 64.1  9.3 64.1  9.3
P .379 .925 .810 .810
Secondary patency
PTA 32 89.5  5.8 75.2  9.6 69.4  10.0 69.4  10.0
Atherectomy 35 90.7  5.1 87.1  6.1 78.8  7.8 78.8  7.8
P .896 .389 .524 .524
Tibial
Primary patency
PTA 96 66.9  5.3 60.8  5.6 51.1  6.2 51.1  6.2
Atherectomy 121 66.4  4.6 56.4  5.0 54.8  5.1 50.2  5.6
P .992 .686 .928 .916
Primary assisted patency
PTA 96 68.1  5.3 63.6  5.5 53.9  6.1 53.9  6.1
Atherectomy 121 73.0  4.3 64.1  4.8 64.1  4.8 61.9  5.1
P .436 .751 .326 .380
Secondary patency
PTA 96 67.8  5.3 66.3  5.4 56.2  6.2 56.2  6.2
Atherectomy 121 80.6  3.8 71.5  4.6 68.4  4.9 66.5  5.1
P .059 .296 .134 .165
Table III. Patency of multilevel CTOs
Patency No. 6 mo 12 mo 18 mo 24 mo
Primary patency
PTA  stent 111 72.6  4.5 49.9  5.7 34.7  6.0 26.1  5.9
PTA 29 67.4  10.4 45.0  11.5 28.1  10.5 22.5  9.8
Ath 71 56.8  6.1 35.7  6.0 28.0  5.8 17.6  5.2
P (PTAS vs PTA) .955 .873 .726 .798
P (PTAS vs Ath) .091 .105 .214 .177
P (PTA vs Ath) .412 .440 .724 .586
Primary assistant patency
PTA  stent 111 77.9  4.2 67.9  5.1 58.0  6.0 53.6  6.3
PTA 29 77.0  9.2 49.5  11.5 44.0  11.5 38.5  11.3
Ath 71 67.4  5.7 50.7  6.3 43.0  6.4 34.8  6.4
P (PTAS vs PTA) .811 .361 .461 .422
P (PTAS vs Ath) .221 .080 .103 .065
P (PTA vs Ath) .399 .875 .808 .720
Secondary patency
PTA  stent 111 81.7  3.9 76.1  4.6 70.0  5.4 67.6  5.7
PTA 29 86.6  7.3 68.7  10.9 61.8  11.8 61.8  11.8
Ath 71 80.6  4.9 67.0  6.0 63.1  6.2 56.7  6.6
P (PTAS vs PTA) .474 .910 .865 .946
P (PTAS vs Ath) .940 .477 .587 .435
P (PTA vs Ath) .605 .842 .964 .738Predictors of Early Graft Failure After Infrainguinal Bypass Surgery: A
Risk-Adjusted Analysis From the NSQIP
Robert T. Lancaster, Mark F. Conrad, Virendra I. Patel, Richard P. Cam-
bria, Glenn L. LaMuraglia1Massachusetts General Hospital, Boston, Mass; 2
Massachusetts General Hospital, Boston, Mass
Introduction and objectives: Infrainguinal bypass surgery (BPG) is
accompanied by significant 30-day mortality and morbidity, including early
graft failure. The goal of this study was to identify patient-specific and
procedure-specific factors that predict the rate of early graft failure in
contemporary practice.
Methods: Data were obtained from the private sector NSQIP, a
prospective, validated database collected between 2005 and 2008 from
211 hospitals, using primary and modifier CPT codes for BPG. The
primary end point was graft failure at 30 days. Procedural parameters,
patient demographics, and clinical variables were analyzed by univariate
and multivariate methods.Results: There were 9217 BPG procedures (limb salvage, 49%; infrap-
opliteal distal anastomosis, 43%; prosthetic 32%) with the following patient
variables: age, 67  12 years; male, 64%; diabetes, 44%; and dialysis, 7.4%.
Mortality was 2.4%, major morbidity was 17.3%, and graft failure rate was
6.3% at 30 days. Multivariate predictors of graft failure demonstrated corre-
lation with female gender (OR, 1.29; P  .0054), limb salvage indication
(OR, 1.60; P  .0001), infrapopliteal anastomosis (OR, 2.15; P  .0001),
composite graft (OR, 1.82; P  .0436), current smoking (OR, 1.36; P 
.0007), impaired sensorium (OR, 2.13; P  .0075), emergency procedure
(OR, 2.03; P .0001), previous vascular procedure (OR, 1.39; P .0005),
and platelets 400 K (OR, 1.49; P  .0019). High-risk composite con-
structs utilizing these significant predictive factors can identify cohorts of
patients with up to a 98-fold increase in odds of early graft failure.
Conclusions:These results describe common risk factors that correlate
with early graft thrombosis, including the unique description of its associa-
tion with thrombocytosis. Additional risk factors thus identify a subset of
patients who may benefit from adjunctive perioperative therapies.
